ATE312087T1 - Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen - Google Patents

Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen

Info

Publication number
ATE312087T1
ATE312087T1 AT98922374T AT98922374T ATE312087T1 AT E312087 T1 ATE312087 T1 AT E312087T1 AT 98922374 T AT98922374 T AT 98922374T AT 98922374 T AT98922374 T AT 98922374T AT E312087 T1 ATE312087 T1 AT E312087T1
Authority
AT
Austria
Prior art keywords
vitamin
compounds
cyclic ether
epi
1alfa
Prior art date
Application number
AT98922374T
Other languages
English (en)
Inventor
Satyanarayana G Reddy
Original Assignee
Woman & Infants Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woman & Infants Hospital filed Critical Woman & Infants Hospital
Application granted granted Critical
Publication of ATE312087T1 publication Critical patent/ATE312087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98922374T 1997-05-16 1998-05-15 Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen ATE312087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4669097P 1997-05-16 1997-05-16
PCT/US1998/010062 WO1998051678A1 (en) 1997-05-16 1998-05-15 CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE312087T1 true ATE312087T1 (de) 2005-12-15

Family

ID=21944848

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98922374T ATE312087T1 (de) 1997-05-16 1998-05-15 Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen

Country Status (8)

Country Link
US (5) US6100294A (de)
EP (1) EP0981523B1 (de)
JP (1) JP2002505668A (de)
AT (1) ATE312087T1 (de)
AU (1) AU743514B2 (de)
CA (1) CA2289209C (de)
DE (1) DE69832699T2 (de)
WO (1) WO1998051678A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19619036A1 (de) * 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US20010007907A1 (en) * 1997-05-16 2001-07-12 Women And Infants Hospital 3-epi compounds of vitamin d3 and uses thereof
AU743514B2 (en) * 1997-05-16 2002-01-24 Women & Infants Hospital Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof
WO1999012894A1 (en) * 1997-09-08 1999-03-18 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
US6531459B1 (en) * 1997-12-17 2003-03-11 Schering Aktiengesellschaft Vitamin D derivatives with phosphorus atoms in the side chains
WO2000061776A1 (en) * 1999-04-14 2000-10-19 Mercian Corporation Vitamin d derivatives and process for producing the same
PT3146969T (pt) * 1999-04-23 2018-10-18 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
WO2001040177A2 (en) 1999-12-02 2001-06-07 Women And Infants Hospital Esters of vitamin d3 and uses thereof
EP1233942A2 (de) * 1999-12-02 2002-08-28 The Penn State Research Foundation Behandlung von entzündlichen darmerkrankungen mit vitamin d-verbindungen
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6753435B1 (en) * 2000-03-30 2004-06-22 Teijin Limited Intermediates for vitamin D and processes for the preparation thereof
WO2001091794A2 (en) 2000-05-30 2001-12-06 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
IL153395A0 (en) * 2000-06-15 2003-07-06 Chugai Pharmaceutical Co Ltd Vitamin d derivatives
WO2002012182A1 (fr) * 2000-08-08 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Derives de 3-methyl-20-epi-vitamine d
WO2002056825A2 (en) * 2000-09-26 2002-07-25 Ganado Research, L.L.C. Composition and method to increase calcium levels in animals
US20050113348A1 (en) * 2003-06-12 2005-05-26 Yanchun Li Vitamin D and vitamin D analogs or derivatives as new anti-hypertensive agents
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
BRPI0404050A (pt) * 2003-09-24 2005-06-14 Bioxell Spa Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
WO2005074943A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha Ｅｄ−７１製剤
AU2005216651A1 (en) 2004-03-01 2005-09-09 Bioxell Spa Treatment of interstitial cystitis with vitamin D compounds
WO2005101022A2 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vitamin d (1,25-dihydroxyvitamin d3) receptor 1 (vdr1)
WO2006036813A2 (en) * 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof
CA2586679A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
EP1863494A1 (de) * 2005-03-23 2007-12-12 Bioxell S.p.a. Verwendung von vitamin-d-verbindungen zur behandlung von endometriose
US20090069276A1 (en) * 2005-04-22 2009-03-12 Novacea, Inc. Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
EP1777220A1 (de) * 2005-09-28 2007-04-25 Centre National de la Recherche Scientifique Vitamin D-Derivate mit Vitamin D nuklear Rezeptor Aktivität, deren Herstellung und deren Verwendung
EP2144872A2 (de) * 2007-04-18 2010-01-20 Johns Hopkins University Gering kalzämische und hoch antiproliferative calcitriol-analoga
WO2009115398A1 (en) * 2008-03-18 2009-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Vitamin d compounds for the treatment of biliary diseases
WO2009153782A1 (en) 2008-06-17 2009-12-23 Ben Gurion University Of The Negev R&D Authority Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
ES2331289B2 (es) * 2008-06-27 2010-06-25 Universidade De Santiago De Compostela Compuestos de la vitamina d deuterados.
WO2012151058A1 (en) 2011-05-03 2012-11-08 Wisconsin Alumni Research Foundation (20s)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin d3 analogs and their uses
US9416102B2 (en) * 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
GB202016614D0 (en) 2020-10-20 2020-12-02 King S College London Compounds
WO2022269768A1 (ja) * 2021-06-22 2022-12-29 学校法人神奈川大学 ビタミンｄ３様化合物
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
CN117126089A (zh) * 2023-08-30 2023-11-28 正大制药（青岛）有限公司 一种氟骨化醇25-羟基消除化合物的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038272A (en) * 1975-10-20 1977-07-26 Hoffmann-La Roche Inc. Stereospecific syntheses of 24r,25- and 24s,25-dihydroxycholesterol and alkanoyl derivatives thereof
US4021423A (en) * 1976-03-08 1977-05-03 Hoffmann-La Roche Inc. Syntheses of 24R,25- and 24S,25-dihydroxycholecalciferol
US4206131A (en) * 1978-06-19 1980-06-03 The Upjohn Company Compounds and process
US4188345A (en) * 1978-07-26 1980-02-12 Wisconsin Alumni Research Foundation Fluorovitamin D compounds and processes for their preparation
GB8304441D0 (en) * 1983-02-17 1983-03-23 Ruskin B E S Beverage dispensing apparatus
US4595776A (en) * 1983-03-21 1986-06-17 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
GB2139627B (en) 1983-05-09 1987-02-04 Wisconsin Alumni Res Found 1 25-dihydroxylated vitamin d2 compounds and intermediates in the preparation thereof
JPS6144860A (ja) * 1984-08-10 1986-03-04 Taisho Pharmaceut Co Ltd １α．２５−ジヒドロキシ−２６．２７−ジメチルビタミンＤ↓３
US5145846A (en) * 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4804502A (en) * 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
KR0144358B1 (ko) * 1988-04-21 1998-07-15 피. 라이달 크리스텐슨 비타민 d 동족체
US5206230A (en) * 1991-06-05 1993-04-27 Daikin Industries, Ltd. Fluorine-containing vitamin D3 analogues and pharmaceutical composition containing the same
US5274142A (en) * 1992-03-12 1993-12-28 The Johns Hopkins University Vitamin D3 analogues
US5830885A (en) * 1992-03-12 1998-11-03 The Johns Hopkins University Antiproliferative vitamin D3 hybrids
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
US5401733A (en) * 1993-10-01 1995-03-28 Hoffmann-La Roche Inc. Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
ZA95906B (en) * 1994-02-07 1996-08-06 Res Developments Foundation Non-viral vector
ATE195513T1 (de) * 1994-04-11 2000-09-15 Chugai Pharmaceutical Co Ltd 22-thiavitamin-d3-derivate
NO971934L (no) * 1996-05-23 1997-11-24 Hoffmann La Roche Flourinerte vitamin D3 -analoger
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
AU743514B2 (en) 1997-05-16 2002-01-24 Women & Infants Hospital Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof

Also Published As

Publication number Publication date
CA2289209A1 (en) 1998-11-19
DE69832699T2 (de) 2006-08-24
US6121312A (en) 2000-09-19
WO1998051678A1 (en) 1998-11-19
CA2289209C (en) 2006-07-25
EP0981523B1 (de) 2005-12-07
AU7493698A (en) 1998-12-08
AU743514B2 (en) 2002-01-24
US6100294A (en) 2000-08-08
EP0981523A1 (de) 2000-03-01
JP2002505668A (ja) 2002-02-19
DE69832699D1 (de) 2006-01-12
US20080188548A1 (en) 2008-08-07
US20030125309A1 (en) 2003-07-03
US6479538B1 (en) 2002-11-12

Similar Documents

Publication Publication Date Title
ATE312087T1 (de) Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen
ATE502932T1 (de) Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
IL136249A0 (en) Suppository containing an acid-labile active compound
BG105564A (en) Galantamine-containing composition with controlled release
MY122383A (en) Cyclic boroproline compounds
DK1157037T3 (da) GCSF-konjugater
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
NZ227131A (en) Compositions for improving cognitive function by administering 1,2-oxazole derivatives
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
MXPA02000973A (es) Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
TR200102800T2 (tr) Yeni bileşikler.
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
WO2001045678A3 (de) Arzneimittel, verfahren zu dessen herstellung und dessen verwendung
MA24643A1 (fr) Tetrahydro-naphtalenes substitues et composes analogues
BG103096A (en) Thrombin inhibitors
ATE293595T1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
WO2001040177A3 (en) Esters of vitamin d3 and uses thereof
DE59800935D1 (en) Immuntolerante prothrombinkomplex-präparation
MXPA02009380A (es) Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilendiamina sustituido por un radical silanico.
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
PL327060A1 (en) Application of 2-ethylhexyl alpha-cyano-beta,beta-diphemylacrylate to improve stability of cosmetic compositions containing p-methylbenzylibene camphor in combination with a derivative of dibenzoyl methane
WO2001009122A3 (en) Serotonergic benzofurans
DE69931807D1 (de) Herstellung von ascorbinsäure unter verwendung von hefe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties